



DEPT. OF HEALTH AND HUMAN SERVICES

Drug Utilization Review Board Meeting Minutes Tuesday March 8, 2022 In-Person Meeting Format Only

The Nebraska Drug Utilization Review (DUR) Board met Tuesday March 8, 2022. The meeting was held in-person only. It originated at the Country Inn Suites in Lincoln, Nebraska.

DUR Board Members in attendance -- Tim Bourke, RP., Tom Dunn, R.P., and Charlie Moore, R.P.

DUR Board Members not in attendance: Susan Howard, MD., Phil Vuchetich, RP; Robert Wergin, MD., Bruce Houghton, M.D., David Randolph, RP., Anthony Ross, M.D.

DHHS attendees: Leah Spencer, R.N., Program Specialist; Spencer Moore, R.P., Dianne Garside, R.P., Ken Saunders, R.P., Director of Pharmacy for Nebraska Medicaid

Contracted attendees: Jamie Benson, RP, Nebraska Total Care; Shannon Nelson, RP, Nebraska HealthyBlue; Bernadette Ueda, RP, United Health Care.

Public in attendance: Erin Hohman, RP, Audrey Ratton, RP

I. Call to Order

The meeting was called to order by Ken Saunders on Tuesday March 8, 2022 at 6:35 pm CDT. Members and attendees were welcomed and asked to introduce themselves. Public attendees were directed to complete a sign-in sheet to be added to the meeting minutes. Ken Saunders made known that meeting materials and the Open-Meetings Law were available.

II. Conflict of Interest

Saunders called for declaration of conflicts of interest. None were declared.

III. Agenda approval

Because there was not a quorum, the Agenda could not be voted upon.

IV. Meeting Minutes from January 11, 2022

There was not a quorum, the Minutes from the January 11, 2022 meeting could not be voted upon.

V. Special Topics

The MME results from the Annual CMS Survey that were reviewed in January 2022, were reviewed again by Saunders. A discussion was had that included how far Nebraska has come in respect to tapering down to 90 MME.

		20 MCO vs. FF3)	(204	IILS	Ш	National MME L	
% o Tota	Count	States (FFS)	Response	% of Total	Total	States (Count of MCOs)	Response
2.08	1	New Hampshire	100 MME	1.72%	4	Massachusetts (1), New Hampshire (3)	100 MME
12.50	6	Hawaii, Massachusetts, Michigan, New Jersey, Washington, Wyoming	120 MME	9.48%	22	California (3), Hawaii (3), Michigan (7), New Jersey (3), Utah (1), Washington (5)	120 MME
12.50	6	Alabama, Alaska, Colorado, Kentucky, Missouri, Tennessee	200 MME	9.91%	23	California (8). Colorado (1). Illinois (2). Kentucky (1). Maryland (1). Michigan (2). New York (6). North Dakota (1). Oregon (1)	200 MME
10.42	5	Indiana, Nevada, Pennsylvania, Vermont, West Virginia	50 MME	5.60%	13	California (1), Georgia (1), Indiana (3), Kentucky (1), Pennsylvania (7)	50 MME
2.08	1	Georgia	80 MME	1.72%	4	Kentucky (1), Ohio (3)	80 MME
54.17	26	Arkansas, Connecticut, Delaware, District of Columbia, Florida, Idaho, Illinois, Iowa, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Montana, Nebraska, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, South Carolina, South Dakota, Texas, Utah, Virginia	90 MME	68.53%		Arkansas (3), California (11), Delaware (2), District of Columbia (4), Florida (15), Georgia (3), Hawaii (3), Illinois (5), Indiana (1), Iowa (2), Kansas (3), Kentucky (2), Louisiana (5), Maryland (8), Massachusetts (3), Michigan (2), Minnesota (8), Mississippi (3), Nobraska (3), Nowado (3), Now Jersey (2), New Mexico (3), New York (11), Ohio (1), Oregon (19), Rhode Island (3), South Carolina (5), Texas (17), Utah (3), Virginia (6)	90 MME
2.08	1	California	> 200 MME	1.72%	4	California (2), Colorado (1), Florida (1)	> 200 MME
4.17	2	Maine, Ohio	<50 MME	1.29%	3	Massachusetts (1), Ohio (1), Pennsylvania (1)	<50 MME
100	48		National Totals	100%	218		National Totals

It was discussed by the DUR Board members in attendance the semi-annual SUPPORT Act data. Saunders related that this includes the use benzodiazepines, opioids, antipsychotics, and gabapentin-type medications. Antipsychotic use in children continues to be an important category for review in the SUPPORT Act. The materials will be reviewed again next meeting. If anything needs to be voted upon, this will be completed once the DUR Board has a quorum. Materials will be available for the DUR Board members prior to the next meeting.

VI. Future Meeting Date

The next DUR Board Meeting is scheduled for Tuesday May 10, 2022 at the Country Inn Suites. The dinner session for the DUR Board members will start promptly at 6:00 PM CDT, with the public session to begin at 6:30 PM CDT. Staffers from the DHHS fee-for-service provider Magellan will also be in attendance.

NEBRASKA DRUG UTILIZATION REVIEW BOARD MEETING MINUTES MARCH 8, 2022

VII. Concerns & Comments

There were no topics discussed or shared by the DUR Board members, the public members or DHHS personnel. Saunders reminded the DUR Board members that the May meeting will again include the review of the six month SUPPORT Act data. Saunders reminded the DUR Board members that the data will be shared with them before the meeting. Please review before the meeting in May.

VIII. Adjournment

The DUR Board adjourned at 7:15 PM.